Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481904 · ClinicalTrials.gov registry record
Registry for Stage 2 Type 1 Diabetes
A clinical trial of Type 1 Diabetes, sponsored by Sanofi.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT06481904 is a study of Type 1 Diabetes that is actively recruiting participants, run by Sanofi. The registered enrollment target is 200 participants, below the 823-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06481904, a study of Type 1 Diabetes, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general information on patients with stage 2 T1D and further information on the long-term effects of TZIELD® in patients with Stage 2 T1D, treated as per standard of care.
Conditions Studied
Interventions
- DRUG TZIELD (teplizumab-mzwv)
Study Locations (20)
Florida
- University of Florida Health- Site Number : 8400035 - Gainesville
- Nemours Children's Speciality Care- Jacksonville- Site Number : 8400006 - Jacksonville
- University of South Florida- Site Number : 8400022 - Tampa
Michigan
- University of Michigan Health System - Ann Arbor- Site Number : 8400028 - Ann Arbor
- Associated Endocrinologists, PC- Site Number : 8400039 - Farmington Hills
- Corewell Health - Grand Rapids - Michigan Street Northeast- Site Number : 8400009 - Grand Rapids
New York
- Women & Children's Hospital of Buffalo- Site Number : 8400018 - Buffalo
- Feinstein Institute for Medical Research (Northwell)- Site Number : 8400016 - Manhasset
- Ten's Medical PC- Site Number : 8400027 - Staten Island
California
- University of California Los Angeles Health- Site Number : 8400020 - Los Angeles
- University of California San Francisco - Mission Bay- Site Number : 8400005 - San Francisco
Colorado
- University of Colorado Hospital- Site Number : 8400026 - Aurora
Connecticut
- Yale University School of Medicine- Site Number : 8400025 - New Haven
Georgia
- Midtown Medical Center - Columbus- Site Number : 8400013 - Columbus
Illinois
- University of Chicago Medical Center- Site Number : 8400017 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2037-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06481904
The ClinicalTrials.gov registry entry for NCT06481904 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 823-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (76% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which TZIELD (teplizumab-mzwv) is the first listed.
NCT06481904 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06481904 about?
NCT06481904 is a clinical study titled "Registry for Stage 2 Type 1 Diabetes". Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to del...
What is the current status of trial NCT06481904?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-09-27. Estimated completion is 2037-01-15.
What conditions does trial NCT06481904 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT06481904?
The interventions under investigation include: TZIELD (teplizumab-mzwv) (DRUG).
Who is sponsoring clinical trial NCT06481904?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481904 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.